HT9427269E001
Other Transaction Agreement
Overview
Government Description
Analgesic Ketamine Product Development
Awardee
Awarding Agency
NAICS
Not Reported
Place of Performance
Singapore
Pricing
Other
Set Aside
None
Extent Competed
Not Competed
Related Opportunity
None
IX Biopharma was awarded
Other Transaction Agreement HT9427269E001 HT9427269E001
for Analgesic Ketamine Product Development
worth up to $40,954,914
by Medical Materiel Development Activity
in February 2026.
The contract
has a duration of 3 years and
was awarded
full & open
with
PSC AN13
via sole source acquisition procedures.
As of today, the Other Transaction Agreement has a total reported backlog of $33,827,183 and funded backlog of $33,827,183.
Status
(Open)
Last Modified 2/6/26
Period of Performance
2/9/26
Start Date
2/8/29
Current End Date
2/8/29
Potential End Date
Obligations and Backlog
$7.1M
Total Obligated
$41.0M
Current Award
$41.0M
Potential Award
$33.8M
Funded Backlog
$33.8M
Total Backlog
Award Hierarchy
Other Transaction Agreement
HT9427269E001
Subcontracts
OTA Details
Type of Agreement
Prototype
Non-Governmental Funding
None Reported
Non-Traditional Participation
Non-Traditional Significant Participation
Activity Timeline
People
Suggested agency contacts for HT9427269E001
Competition
Number of Bidders
Not Applicable
Solicitation Procedures
Sole Source
Evaluated Preference
None
Commercial Item Acquisition
None
Simplified Procedures for Commercial Items
None
Other Categorizations
Subcontracting Plan
Not Required
Cost Accounting Standards
Exempt
Business Size Determination
Large Business
Defense Program
None
DoD Claimant Code
None
Awardee UEI
UJ73DZNC8HW4
Awardee CAGE
Q4132
Agency Detail
Awarding Office
HT9427 DEFENSE HEALTH AGENCY
Funding Office
W806YH
Created By
christopher.m.sult@otafaaadc
Last Modified By
julia.l.burns3.civ@health.mil
Approved By
julia.l.burns3.civ@health.mil
Legislative
Legislative Mandates
None Applicable
Performance District
Not Applicable
Modified: 2/6/26